Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sulfadiazine zinc is a topical antimicrobial agent consisting of the zinc salt of sulfadiazine, primarily indicated for the prevention and treatment of infection in burn wounds. As a sulfonamide antibiotic, it functions by competitively inhibiting the enzyme dihydropteroate synthase (DHPS), which is critical for bacterial folic acid synthesis, thereby providing broad-spectrum bacteriostatic activity. The zinc component of the molecule enhances the therapeutic profile by promoting re-epithelialization and wound healing, while also offering mild astringent and antimicrobial properties. In clinical practice, particularly in China, it is often formulated as a 'compound' gel and has been evaluated in Phase 4 trials for second-degree burns as an alternative to silver sulfadiazine, aiming to provide effective infection control and wound closure without the risk of silver-associated skin staining.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sulfadiazine zinc.